Human Papillomavirus in Cervical Cancer and Pre-cancer in Switzerland: The CIN3+Plus Study
CIN3+plus
Human Papillomavirus-Associated Cervical Neoplasia in Switzerland at the Start of a National Vaccination Programme: Crosssectional Study
1 other identifier
observational
767
1 country
10
Brief Summary
This study will investigate the types of HPV in samples from women with cervical pre-cancer and cancer and gather information to help investigate the impact of HPV vaccination in Switzerland.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2015
10 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 18, 2014
CompletedFirst Posted
Study publicly available on registry
December 24, 2014
CompletedStudy Start
First participant enrolled
January 1, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2016
CompletedJuly 16, 2019
July 1, 2019
11 months
December 18, 2014
July 12, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Human papillomavirus presence and type
2 years
Eligibility Criteria
Women with histologically confirmed CIN3+ lesions
You may qualify if:
- Participant is willing and able to give informed consent for participation in the study.
- Participant is literate in German, French, Italian or English.
- Female, aged 18 years or above.
- Histologically confirmed CIN3+ lesions, i.e. CIN3, adenocarcinoma in situ and invasive carcinoma of the cervix.
- Participant resides in the canton Zurich, Geneva, Basel, Baselland, Luzern or Ticino.
You may not qualify if:
- None
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Bernlead
- Federal Office of Public Health, Switzerlandcollaborator
Study Sites (10)
Viollier AG
Allschwil, Basel-Landschaft, 4123, Switzerland
Universitätsspital Basel
Basel, Switzerland
Viollier Weintraub SA
Geneva, 1206, Switzerland
HUG - Hôpitaux Universitaires de Genève
Geneva, Switzerland
Kantonsspital Baselland
Liestal, Switzerland
Istituto cantonale di patologia
Locarno, Switzerland
Kantonsspital Luzern
Lucerne, Switzerland
Institute of Pathology Enge
Zurich, 8002, Switzerland
Institut für klinische Pathologie Medica
Zurich, 8024, Switzerland
Universitätsspital Zürich
Zurich, Switzerland
Related Publications (1)
Egli-Gany D, Spaar Zographos A, Diebold J, Masserey Spicher V, Frey Tirri B, Heusser R, Dillner J, Petignat P, Sahli R, Low N; CIN3+plus study group. Human papillomavirus genotype distribution and socio-behavioural characteristics in women with cervical pre-cancer and cancer at the start of a human papillomavirus vaccination programme: the CIN3+ plus study. BMC Cancer. 2019 Jan 30;19(1):111. doi: 10.1186/s12885-018-5248-y.
PMID: 30700274RESULT
Biospecimen
Histologically confirmed CIN3+ lesions, i.e. CIN3, adenocarcinoma in situ and invasive carcinoma of the cervix.
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Nicola Low
University of Bern, Institute of Social and Preventive Medicine
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 18, 2014
First Posted
December 24, 2014
Study Start
January 1, 2015
Primary Completion
December 1, 2015
Study Completion
May 1, 2016
Last Updated
July 16, 2019
Record last verified: 2019-07